Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC By Ogkologos - April 30, 2026 146 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Breast Cancer Survivor And Teenage Son Hand-Sew Neck Pillows To Bring... August 15, 2019 FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma November 13, 2023 Ovarian Function Suppression Plus Tamoxifen Significantly Reduces Premenopausal Breast Cancer Recurrence... July 6, 2026 Mathew Knowles, Father Of Beyoncé, Fought And Beat Breast Cancer November 5, 2019 Load more HOT NEWS Adding Sintilimab to Chemoradiotherapy Improves Event-Free Survival in Patients with High-Risk... Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women... ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΝΕΥΜΟΝΑ:ΝΕΑ ΜΕΛΕΤΗ, ΝΕΕΣ ΕΛΠΙΔΕΣ FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs...
